Suppr超能文献

与肾透明细胞外肾细胞癌患者细胞减灭性肾切除术后生存相关的临床病理特征。

Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.

机构信息

Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.

Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Urol Oncol. 2019 Nov;37(11):811.e9-811.e16. doi: 10.1016/j.urolonc.2019.07.011. Epub 2019 Sep 12.

Abstract

OBJECTIVES

To report the overall survival (OS) outcomes of patients with nonclear cell renal cell carcinoma (nccRCC) treated at our institution with a cytoreductive nephrectomy (CN) and better understand the clinical and pathological characteristics of the patients that respond best.

MATERIAL AND METHODS

We queried our prospectively maintained database for patients who underwent CN for nccRCC between 1989 and 2018. Histology was reviewed by an expert genitourinary pathologist, and nccRCC tumors were subdivided into papillary, unclassified, chromophobe, and other histology. Baseline clinicopathology, treatments, and survival outcomes were recorded. Preoperative hematological parameters including the neutrophil-to-lymphocyte ratio (NLR) were analyzed. Significant univariate predictors of OS were tested in a multivariate model.

RESULTS

There were 100 nccRCC patients treated with CN. Median age was 61 years (IQR: 48-69) and 65% were male. There were 79 patient deaths with a median OS of 13.7 months (10.8-27.2). Estimated 2- and 5-year survival was 40.1% and 12.2%, respectively. Median follow-up of survivors was 13 months (IQR: 3-30). On multivariate analysis, increasing NLR (hazard ratio [HR] 1.27; 95% confidence interval [CI] 1.14-1.40, P < 0.001) and sarcomatoid features (HR 2.18; 95% CI 1.19-3.97, P = 0.014) conferred worse OS and the presence of papillary features were a favorable prognostic feature (HR 0.37; 95% CI 0.21-0.65, P < 0.001).

CONCLUSIONS

OS outcomes in patients with nccRCC who underwent a CN are consistently modest throughout the study period. Patients with papillary features and a lower preoperative NLR may be better candidates for a CN.

摘要

目的

报告在本机构接受细胞减瘤性肾切除术(CN)治疗的非透明细胞肾细胞癌(nccRCC)患者的总生存(OS)结果,并更好地了解对治疗反应最佳的患者的临床和病理特征。

材料与方法

我们通过前瞻性维护的数据库查询了 1989 年至 2018 年间接受 nccRCC 行 CN 的患者。由泌尿生殖系统病理专家对组织学进行了复查,将 nccRCC 肿瘤分为乳头状、未分类、嫌色细胞和其他组织学。记录了基线临床病理特征、治疗和生存结果。分析了术前血液学参数,包括中性粒细胞与淋巴细胞比值(NLR)。在多变量模型中对 OS 的显著单变量预测因素进行了测试。

结果

共 100 例 nccRCC 患者接受 CN 治疗。中位年龄为 61 岁(IQR:48-69),65%为男性。79 例患者死亡,中位 OS 为 13.7 个月(10.8-27.2)。估计 2 年和 5 年生存率分别为 40.1%和 12.2%。幸存者的中位随访时间为 13 个月(IQR:3-30)。多变量分析显示,NLR 升高(风险比 [HR] 1.27;95%置信区间 [CI] 1.14-1.40,P<0.001)和肉瘤样特征(HR 2.18;95%CI 1.19-3.97,P=0.014)与更差的 OS 相关,而存在乳头状特征是预后良好的特征(HR 0.37;95%CI 0.21-0.65,P<0.001)。

结论

在接受 CN 治疗的 nccRCC 患者中,OS 结果在整个研究期间一直较为稳定。具有乳头状特征和较低术前 NLR 的患者可能是 CN 的更好候选者。

相似文献

1
Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.
Urol Oncol. 2019 Nov;37(11):811.e9-811.e16. doi: 10.1016/j.urolonc.2019.07.011. Epub 2019 Sep 12.
2
Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
J Urol. 2007 Nov;178(5):1896-900. doi: 10.1016/j.juro.2007.07.037. Epub 2007 Sep 17.
6
The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience.
Urology. 2020 Feb;136:169-175. doi: 10.1016/j.urology.2019.08.058. Epub 2019 Nov 11.
7
The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
Urol Oncol. 2019 Dec;37(12):916-923. doi: 10.1016/j.urolonc.2019.09.006. Epub 2019 Oct 4.
10
The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
Eur Urol Focus. 2020 Jan 15;6(1):104-111. doi: 10.1016/j.euf.2018.08.023. Epub 2018 Sep 8.

引用本文的文献

2
Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.
J Cancer Res Clin Oncol. 2023 Sep;149(12):9657-9670. doi: 10.1007/s00432-023-04885-x. Epub 2023 May 25.
3
Systemic Immunological Determinants of Oncological Outcomes After Surgery for Localized Renal Cell Carcinoma.
Clin Genitourin Cancer. 2022 Oct;20(5):e432-e439. doi: 10.1016/j.clgc.2022.05.010. Epub 2022 May 25.
4
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.
Cancer. 2021 Nov 1;127(21):3946-3956. doi: 10.1002/cncr.33790. Epub 2021 Jul 19.
5
Nomograms-based prediction of overall and cancer-specific survivals for patients with chromophobe renal cell carcinoma.
Exp Biol Med (Maywood). 2021 Mar;246(6):729-739. doi: 10.1177/1535370220977107. Epub 2020 Dec 10.

本文引用的文献

1
Cancer statistics, 2019.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
4
The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
Eur Urol Focus. 2020 Jan 15;6(1):104-111. doi: 10.1016/j.euf.2018.08.023. Epub 2018 Sep 8.
6
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
7
Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Oncotarget. 2018 Feb 16;9(18):14296-14305. doi: 10.18632/oncotarget.24507. eCollection 2018 Mar 6.
9
Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Eur Urol Focus. 2019 May;5(3):488-496. doi: 10.1016/j.euf.2017.11.012. Epub 2017 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验